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Abstract
Background: Mutations in Phenylalanine Hydroxylase (PAH) gene cause phenylketonuria. Sapropterin (BH4), the
enzyme cofactor, is an important therapeutical strategy in phenylketonuria. However, PAH is a highly polymorphic
gene and it is difficult to identify BH4-responsive genotypes. We seek here to improve prediction of BH4-
responsiveness through comparison of genotypes, BH4-loading test, predictions of responsiveness according
to the literature and types and locations of mutations.
Methods: A total of 364 French patients among which, 9 % had mild hyperphenylalaninemia, 17.7 % mild
phenylketonuria and 73.1 % classical phenylketonuria, benefited from a 24-hour BH4-loading test and had
the PAH gene sequenced and analyzed by Multiplex Ligation Probe Amplification.
Results: Overall, 31.6 % of patients were BH4-responsive. The number of different mutations found was 127,
including 26 new mutations. The mutations c.434A > T, c.500A > T, c.529G > C, c.1045 T > G and c.1196 T > C
were newly classified as being BH4-responsive. We identified 261 genotypes, among which 46 were newly
recognized as being BH4-responsive. Even though patients carry 2 responsive alleles, BH4-responsiveness
cannot be predicted with certainty unless they present mild hyperphenylalaninemia. BH4-responsiveness
cannot be predicted in patients carrying one responsive mutation only. In general, the milder the phenotype
is, the stronger the BH4-response is. Almost exclusively missense mutations, particularly in exons 12, 11 and 8,
are associated with BH4-responsiveness and any other type of mutation predicts a negative response.
Conclusions: This study is the first of its kind, in a French population, to identify the phenotype associated
with several combinations of PAH mutations. As others, it highlights the necessity of performing
simultaneously BH4 loading test and molecular analysis in monitoring phenylketonuria patients.
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Background
Phenylketonuria (PKU, OMIM 261600) is an autosomal
recessive disorder caused by a deficient hepatic phenyl-
alanine hydroxylase (PAH) activity [1]. To date, no less
than 890 disease causing mutations have been registered
to the BioPKU database [2]. In general, the genotype dic-
tates the phenotype [3]. Individuals with simultaneous
presence of two null alleles exhibit the classic PKU
(cPKU) phenotype, whereas individuals with mutations
bearing residual enzyme activity display the mild PKU
(mPKU) or the mild hyperphenylalaninemia (mHP).
PAH is a homotetrameric or homodimeric enzyme,
whose activity is regulated by the binding of its substrate,
Phenylalanine (Phe), and its cofactor, tetrahydrobiop-
terin (BH4). Each subunit of this multimeric enzyme
is composed of the regulatory, the catalytic and the
oligomerization domains [4].
The mainstay of the treatment for PKU remains the
low-phenylalanine diet [5]. Additional strategy involv-
ing the use of sapropterin, a specific pharmacological
chaperone similar to the physiologic cofactor tetrahydro-
biopterin, is being introduced [6]. Sapropterin enhances
PAH enzymatic activity, through multiple mechanisms
including (1) stabilization of PAH dimer/tetramer, (2)
up-regulation of gene expression, and (3) stabilization
of mRNA [4, 7, 8]. However, sapropterin is not efficient in
all patients. The degree of sapropterin-responsiveness de-
pends on the presence of responsive mutations [9] having
still residual PAH activity [10]. Since PAH is a multimeric
protein, it depends also on the allelic complementation of
the particular genotype [11, 12].
Numerous studies have investigated mutations in the
PAH gene as well as prediction of BH4-responsiveness
based on genotypes. However, only few have additionally
performed BH4-loading tests [13–20]. Thus the status of
several genotypes is unknown and whether they are
BH4-responsive or not needs to be clarified.
We have performed a systematical research of
mutations in French PKU patients and systematically
evaluated the response to oral BH4-loading test. The aim
was to improve the prediction of BH4-responsiveness
by relating genetic information such as type, location




A total of 364 hyperphenylalaninemic patients, including
42 siblings, were investigated. They represented mixed ori-
gin people from 20 French Centers for Inborn Errors of
Metabolism. According to their blood Phenylalanine con-
centration at time of diagnosis, these patients were
assigned to one of the three phenotype categories: mild hy-
perphenylalaninemia (mHP, 180 < Phe < 600 μmol/L); mild
phenylketonuria (mPKU, 600 < Phe < 1200 μmol/L) and
classical phenylketonuria (cPKU, Phe > 1200 μmol/L) [21].
BH4-responsiveness
The BH4 oral loading test protocol has been standardized
and published in the French High Health Authority
(HAS) 2010 recommendations [22]. Patients were consid-
ered as BH4-responsive if an oral bolus of BH4 dose
(20 mg/kg body weight) lowered blood Phe concentration
by at least 30 % at one time point within 24 hours. In
35 % of patients, BH4-loading test was performed during
the neonatal period, in 42 % between 1 month and 18
years and in 23 % during adulthood.
DNA isolation, PCR amplification, dHPLC (denatured High
Performance Liquid Chromatography) and sequencing
Informed consent for genotype assessment was obtained
from patients (or parents) for being included in the
study. Genotyping analyses were conducted in a single
laboratory. Genomic DNA was extracted from blood
samples using the Nucleon BACC3 Genomic DNA
Extraction Kit (GE Healthcare). PCR was carried out
with 13 sets of oligonucleotides amplifying all 13 exons
of the gene and the exon-intron junctions. Amplicons
were separated by dHPLC as previously reported [23].
Fragments showing an abnormal dHPLC pattern were
purified (Qiaquick PCR purification kit, Qiagen), quanti-
fied and sequenced using the ABI PRISM Big Dye termin-
ator V1.1 sequencing kit and the 3100-Avant Genetic
Analyzer (Applied Biosystems). When no mutation was
identified with dHPLC, all exons were sequenced.
Multiplex Ligation-dependent Probe Amplification
(MLPA) analysis
When only one mutation was found, MLPA analysis was
performed with the SALSA MLPA kit P055 (MRC) in
order to detect large deletions or duplications.
Variants classification
A mutation was considered as novel if not listed in the
NCBI database [24] and hence was submitted to this
database. An unclassified mutation was considered as
BH4-responsive when BH4 challenging was positive and
the genotype was either homozygous for this mutation
or compound heterozygous combining this mutation
with a null mutation [10, 12]. A null mutation is a non-
sense mutation or a mutation yielding a protein with less
than 1 % predicted residual activity (PRA). If a homozy-
gous genotype was found to be associated with unrespon-
siveness in at least five patients, the mutated allele was
considered as non-responsive. In addition, a genotype was
newly recognized as responsive if 1) there was at least one
responsive patient in the present study and 2) it was not
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previously described at the BioPKU database. All geno-
types have been submitted to the BioPKU database [2].
Molecular modeling
Missense mutations newly described as BH4-responsive
were modeled by in silico analysis using Pymol molecu-
lar visualization system and the published structure of
truncated PAH with Protein Data Bank entry 1MMK
(catalytic domain and dimerization motif ).
Secondary structure was drawn with Dog 2.0 software
using information from Erlandsen and colleagues [25],
UniprotKB/Swissprot (P00439) and NCBI Reference
sequence NP_000268.1.
Statistical analysis
Statistical analysis was performed by using the SAS
software package version 9.3 (SAS Institute). Genotypes,
mutations and related descriptive characteristics were pre-
sented as frequency, mean and/or percentage. Associations
were tested using t-test, Chi-square (Chi-2) or Fisher's
exact tests. Tests were judged significant at p ≤ 0.05.
Results
Phenotype distribution
Thirty-three patients were identified as mHP (9 %), 65
as mPKU (17.7 %) and 266 as cPKU (73.1 %). Patients
with siblings similarly affected by PKU appeared to share
the same phenotype. 24 hours after BH4-loading
approximately one third of patients (31.6 %) experienced
a reduction in their Phe concentration of at least 30 %.
Overall, more responders were found in groups with the
less severe phenotypes, with the positive response rate at
90.9 % for mHP, 69.2 % for mPKU and 14.7 % for cPKU,
respectively (p < 0.0001; Fisher exact test) (Additional
file 1: Figure S1). In addition, the milder the phenotype is,
the higher the response rate is. Indeed, 71 % of mHP with
a positive test versus 37 % of cPKU with a positive test
presented with a responsive rate higher than 50 %.
mHP patients BH4 responders were tested at initial
Phe concentrations at the start of BH4-testing (H0)
ranking between 114 and 990 μmol/L (mean = 366).
Three patients among 33 with mHP were BH4 non-
responsive (c.[1045 T > C]; [1243G > A] (p. [Ser349-
Pro]; [Asp415Asn]); c. [734 T > C]; [1315 + 1G > A] (p.
[Val245Ala]; [?]) and c. [261C > A]; [1065 + 1G > A] (p.
[Ser87Arg]; [?]) genotypes). Two of them were tested
between 3 and 18 yo, both at initial Phe concentration of
144 μmol/L, lower that minimum concentration required
for testing. For PKU, there was no difference in Phe
concentration at the start of BH4 testing between
responsive aPKU (n = 37; mH0 = 600 μmol/L (216–
1116)) and non-responsive aPKU (n = 15; mH0 =
672 μmol/L (318–1026)) neither between responsive
cPKU (n = 29; mH0 = 1206 μmol/L (342–2160)) and non-
responsive cPKU (n = 170; mH0 = 1374 μmol/L (300–
4320)) (T-test; p values = 0.28 and 0.22 respectively).
Mutation detection rate and mutations spectrum
No mutation was found for one classical PKU patient
and only a single heterozygous pathogenic mutation
could be identified in one mHP, 2 mPKU and 2 cPKU.
Twelve deletions and one duplication were found by
MLPA. Mutation detection rate was 97.3 % with sequen-
cing alone and 99.05 % when combined with MLPA.
A total of 127 different mutations were detected among
which 26 new ones. Mutations were mapped to the cata-
lytic (63.8 %), regulatory (17.3 %) and oligomerization
(2.4 %) domains and 15.7 % localized in intronic regions.
One deletion spanned across catalytic and oligomerization
domains. Mutations types were as follows: 59.8 %
missense, 15.7 % splice-site, 9.4 % frameshift small
deletions or insertions, 8.7 % nonsense mutations, as well
as 3.9 % large deletions, 1.6 % in-frame small deletions or
duplications and 0.8 % large duplications.
Sixty-one mutations were private mutations. The most
frequent mutation found was c.1066-11G > A (8.6 %).
Some of the most frequent alleles (frequency >1 %) were
significantly associated with the severity of the clinical
phenotype like c.1066-11G > A (PRA 0) and c.1055delG
(p.Gly352Valfs*48) (Fisher exact test, p < 0.05). On the
other hand, c.1241A > G (p.Tyr414Cys), c.1169A > G
(p. Glu390Gly), c.1208C > T (p.Ala403Val), c.204A > T
(p.Arg68Ser) and c.898G > T (p.Ala300Ser), known to
have PRA >30 %, were associated with moderate pheno-
types (mHP and mPKU, Fisher exact test, p < 0.001).
Although predicted residual activity of c.782G >A
(p.Arg261Gln) is 38.5, this mutation was found to be more
frequent in the cPKU group (Fisher exact test, p < 0.05).
Mutations responsiveness to BH4
Data available in the literature indicated that among
the 127 pathogenic mutations we found, 28 are BH4-
responsive and 17 BH4-unresponsive. Among the 82
left mutations, we succeeded in classifying 5 as BH4-
responsive and 7 as BH4-unresponsive while the 70
others remained with an unknown status. The new
mutation c.1196 T > C (p.Val399Ala) was considered
BH4-responsive since after BH4-loading test (initial
Phe concentration 1020 μmol/L), a 97 % decrease in
Phe concentration was observed in a compound
heterozygous patient carrying this mutation with
c.1066-11G > A mutation generating a protein with
negligible residual activity. Similar conclusion was
drawn for the c.1045 T >G mutation (p.Ser349Ala) since
positive BH4-responses were observed in one homozygous
mPKU patient and another compound heterozygous
patient carrying an additional non-responsive allele.
The mutations c.434A > T (p.Asp145Val), c.500A > T
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(p.Asn167Ile) and c.529G > C (p.Val177Leu) were also
classified as BH4-responsive since they were found in
compound heterozygous patients carrying a second
null mutation. These mutations were mapped to the
catalytic domain of the protein and are shown on a
modeled tridimensional structure representing the PAH
protein complexed with BH4, thienylalanine (analog
substrate) and iron (Additional file 2: Figure S2 and
Additional file 3: Figure S3). Another group of five
unclassified mutations fitted the criteria to be classified as
responsive mutations: c.266_267insC (p.Ala90Cfs*12),
c.1249 T >A (p.Tyr417Asn), c.887A >G (p.Asp296Gly
newly described mutation), c.1199 + 1G >C and c.493G >
A (p.Ala165Thr) but where classified as unclear especially
because they were observed in patients with a BH4-
responsive rate comprised between 30 and 40 percent (see
Discussion). Thus c.[266_267insC]; [842C > T] genotype
was observed in one patient displaying a 36 % decrease in
Phe concentration (H0 1560 μmol/L; tested between 3
and 10 yo) and c. [1249 T >A]; [1315 + 1G >A] genotype
was observed in one mPKU with a 37 % decrease in Phe
concentration (H0 702 μmol/L; neonatal test). The
c.887A >G (p.Asp296Gly) mutation was found in one
patient combined with the non-responsive c.1222C > T
mutation (p. Arg408Trp). This patient showed a 36 %
decrease in Phe concentration (H0 1326 μmol/L; tested
between 10 and 18 yo), however p.Arg408Trp mutation is
proposed to have a dominating negative effect [20]. One
cPKU patient with c. [1199 + 1G > C]; [1066-11G > A]
genotype showed a 37.5 % Phe concentration decrease
(H0 1152 μmol/L; tested between 10 and 18 yo) but 1
mPKU ((H0 822 μmol/L; tested between 3 and 10 yo) and
1 cPKU (H0 3258 μmol/L; tested as neonate) with the
same genotype were non-responsive. In addition, one
homozygote c. [1199 + 1G > C]; [1199 + 1G >C] cPKU
were non-responsive (H0 1842 μmol/L; tested at adult-
hood). Finally, c. [493G > A]; [493G > A] genotype was ob-
served in two cPKU siblings. The one tested between 3
and 10 years of age showed no decrease in Phe concentra-
tion (H0 384 μmol/L) while the one tested in the neonatal
period showed a 36 % decrease (H0 1680 μmol/L) but is
not currently under BH4 treatment.
Conversely, 6 nonsense mutations – coding for
p.Glu57*, p.Glu66*, p.Tyr168*; p.Tyr216*, p.Asp222*,
p.Glu280*, and the deletion c.1055delG (p.Gly352Vfs*48),
observed in 7 homozygous patients with no response to
BH4 challenging, were considered as BH4-unresponsive.
Genotype-phenotype associations
In Table 1, the BH4-loading tests for the 261 tabulated
genotypes are listed together with the relative frequency
and associated PKU phenotypes. Most of the genotypes
were associated with a unique class of PKU severity. How-
ever, c. [194 T >C]; [1208C >T] (p.[Ile65Thr]; [Ala403Val],
n = 3) and c. [1208C >T]; [1222C > T] (p.[Ala403Val];
[Arg408Trp], n = 2) genotypes were associated with both
mHP and mPKU and 12 other genotypes (n = 36) were ob-
served in both mPKU and cPKU. In addition, c. [1223G >
A]; [1241A >G] (p.[Arg408Gln]; [Tyr414Cys], n = 2) was
inconsistently associated with mHP and cPKU.
The most frequent genotype (n = 11, 4.2 %) was c.
[838G > A]; [838G > A] (p.[Glu280Lys]; [Glu280Lys]).
Overall, 21 genotypes had a frequency higher than 1 %
(n ≥ 3). Among them, the observed phenotype was con-
sistent with the predicted phenotype (according to the
predictive residual activity) for the severe mutations
only. Indeed, individuals with a combination of two
mutations with low PRA (<2) were consistently associ-
ated with either mPKU or most often with cPKU. Three
genotypes, c. [782G > A]; [782G > A] (p.[Arg261Gln];
[Arg261Gln], n = 8), c. [194 T > C]; [782G > A] (p.
[Ile65Thr]; [Arg261Gln], n = 3) and c. [143 T > C];
[143 T > C] (p. [Leu48Ser]; [Leu48Ser], n = 3), were asso-
ciated to severe cPKU or mPKU phenotypes despite high
residual activity for both mutations (p.Arg261Gln: PRA
38.5; p.Ile65Thr: PRA 25.3; p.Leu48Ser: PRA 39). In
addition, in genotypes combining a mild mutation (PRA >
20) and a severe mutation (PRA < 2), mild mutation did
not always dominate. For example, c. [782G > A]; [1315 +
1G >A] (p. [Arg261Gln]; [?], n = 5), c. [1222C > T];
[1241A >G] (p. [Arg408Trp]; [Tyr414Cys], n = 5), c.
[194 T > C]; [1066-11G > A] (p.[Ile65Thr]; [?], n = 4)
and c. [782G > A]; [1066-11G > A] (p.[Arg261Gln]; [?],
n = 4) were all associated with either cPKU or mPKU.
A total of 36.7 % of all genotypes included at least one
BH4-responsive patient. 83 genotypes displayed a re-
sponse rate higher than 40 % and 9 genotypes displayed
a response between 30 % and 40 %. This includes 46
genotypes newly described as BH4-responsive. Among
all patients, 215 displayed a genotype consisting of two
alleles whose BH4-responsiveness was reported in the
literature. Among those, 51 were carriers of 2 alleles pre-
viously expected to be BH4-responsive. However, only
66.7 % (34/51) responded positively to the BH4-loading
test. Indeed, 100 % of mHP patients carrying 2 BH4-
responsive alleles responded to BH4 administration but
only 85.7 % of mPKU and 42.3 % of cPKU patients
(Additional file 4: Figure S4). The presence of a single
responsive mutation predicted a high rate of responsive-
ness in mHP (84.6 %) and mPKU (73.1 %) patients, while
only 13.5 % of cPKU patients carrying one responsive mu-
tation and one non-responsive mutation exhibited positive
BH4-loading test (Additional file 4: Figure S4). Another 50
of the 215 patients whose BH4-responsiveness could be
predicted according to the literature, carried two non-
responsive alleles. In these patients, the observed pheno-
type matched the predicted phenotype in all but two
(Additional file 4: Figure S4), who experienced decrease,
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mHP mPKU cPKU mut1 mut2 mut3 mut1 mut2
c. [1A > G]; [782G > A] p. [Met1Val]; [Arg261Gln] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk Ra
(38.5)
-
c. [60G > C]; [473G > A] p. [Gln20His];
[Arg158Gln]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk R (10) -
c. [60 + 5G > A]#; [1042C >
G]
p. [?]; [Leu348Val] 1 (0.38) - - 1 (0/
1)





1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (20) R (41) -
c. [115_117delTTC]; [1315 +
1G>A]
p. [Phe39del]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) R (20) NR (0) -
c. [117C > G]; [785 T > G]# p. [Phe39Leu];
[Val262Gly]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (49) unk -
c. [117C > G]; [814G > T] p. [Phe39Leu]; [Gly272*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (49) NR (1) -
c. [117C > G]; [1169A > G] p. [Phe39Leu];
[Glu390Gly]
1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 no data R (49) R
(72.5)
-






0 37 R; 5 NR R (39) R (39) -
c. [143 T > C]; [165delT] p. [Leu48Ser];
[Phe55Leufs*6]
2 (0.77) - - 2 (2/
0)
2 (cPKU) 0 2 PKU R R (39) unk -
c. [143 T > C]; [526C > T] p. [Leu48Ser]; [Arg176*] 1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 no data R (39) NR (1) -




1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (39) unk -
c. [143 T > C]; [782G > A] p. [Leu48Ser];
[Arg261Gln]
2 (0.77) - - 2 (2/
0)
2 (cPKU) 0 22 R; 5 NR R (39) Ra
(38,5)
-
c. [143 T > C]; [1045 T > C] p. [Leu48Ser];
[Ser349Pro]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (39) NR (1) -
c. [143 T > C]; [1055delG] p. [Leu48Ser];
[Gly352Valfs*48]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (39) unk - NR
c. [143 T > C]; [1066-11G >
A]

















Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)
c. [143 T > C]; [1162G > A] p. [Leu48Ser];
[Val388Met]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 2 mPKU R R (39) R
(27,5)
-
c. [143 T > C]; [442-?_509
+ ?del]
p. [Leu48Ser]; [Ex5del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (39) unk -
c. [155delT]#; [781C > T] p. [Leu52Cysfs*9];
[Arg261*]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (1) -
c. [158G > A]; [?] p. [Arg53His]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 unk
(79)
- -
c. [164 T > C]#; [1066-
11G > A]
p. [Phe55Ser]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [165delT]; [194 T > C] p. [Phe55Leufs*6];
[Ile65Thr]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk R
(25,3)
-
c. [165delT]; [441 + 5G > T] p. [Phe55Leufs*6]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) unk NRb -
c. [165delT]; [727C > T] p. [Phe55Leufs*6];
[Arg243*]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (1) -
c. [165delT]; [1066-11G >
A]
p. [Phe55Leufs*6]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [165delT]; [1315 + 1G >
A]
p. [Phe55Leufs*6]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [168 + 5G > C]; [168 +
5G > C]
p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [168 + 5G > C]; [782G >
A]
p. [?]; [Arg261Gln] 2 (0.77) - - 2 (1/
1)





c. [168 + 5G > C]; [1-?_60
+ ?del]#
p. [?]; [Ex1del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [169G > T]#; [194 T > C] p. [Glu57*]; [Ile65Thr] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk R
(25,3)
- NR
c. [194 T > C]; [204A > T] p. [Ile65Thr]; [Arg68Ser] 1 (0.38) - 1 (1/
0)





c. [194 T > C]; [331C > T] p. [Ile65Thr]; [Arg111*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
NR (1) -
c. [194 T > C]; [386A > G] p. [Ile65Thr]; [Asp129Gly] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
R -
c. [194 T > C]; [473G > A] p. [Ile65Thr]; [Arg158Gln] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
R (10) -
c. [194 T > C]; [526C > T] p. [Ile65Thr]; [Arg176*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
NR (1) -




















c. [194 T > C]; [782G > C] p. [Ile65Thr]; [Arg261Pro] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
unk -
c. [194 T > C]; [829 T > G] p. [Ile65Thr]; [Tyr277Asp] 1 (0.38) - 1 (0/
1)





c. [194 T > C]; [838G > A] p. [Ile65Thr]; [Glu280Lys] 1 (0.38) - - 1 (0/
1)





c. [194 T > C]; [842C > T] p. [Ile65Thr]; [Pro281Leu] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) R
(25.3)
NR (1) -
c. [194 T > C]; [842 + 1G> A] p. [Ile65Thr]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
unk -
c. [194 T > C]; [844G > A] p. [Ile65Thr];
[Asp282Asn]
1 (0.38) - - 1 (0/
1)





c. [194 T > C]; [898G > T] p. [Ile65Thr]; [Ala300Ser] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 2 mHP R R
(25.3)
R (31) -
c. [194 T > C]; [912 + 1G> A] p. [Ile65Thr]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
unk -
c. [194 T > C]; [916A > G] p. [Ile65Thr]; [I306Val] 1 (0.38) - 1 (1/
0)






c. [194 T > C]; [932 T > C] p. [Ile65Thr]; [Leu311Pro] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
NR (1) -
c. [194 T > C]; [1042C > G] p. [Ile65Thr]; [Leu348Val] 1 (0.38) - 1 (1/
0)





c. [194 T > C]; [1045 T > C] p. [Ile65Thr]; [Ser349Pro] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R
(25.3)
NR (1) -
c. [194 T > C]; [1066-11G >
A]
p. [Ile65Thr]; [?] 4 (1.53) - - 4 (0/
4)
0 4 (4 cPKU) R
(25.3)
NR (0) -















1 (0.38) - - 1 (1/
0)









- 2 (2 mHP) 1 (PKUa) minus
15 %
1 mHP R R
(25.3)
R (32) -
c. [194 T > C]; [1222C > T] p. [Ile65Thr]; [Arg408Trp] 2 (0.77) - - 2 (1/
1)
1 (cPKU) minus 32 % 1 (cPKU) minus
14 %
9 R; 8 NR R
(25.3)
NR (1) -
c. [196G > T]#; [1315 +
1G > A]
p. [Glu66*]; [?] 1 (0.38) - - 1 (0/
1)













Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)
c. [204A > T]; [204A > T] p. [Arg68Ser]; [Arg68Ser] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 1 mPKU R R (87) R (87) -




1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (87) unk -




1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data R (87) NR (1) unk
c. [204A > T]; [611A > G] p. [Arg68Ser];
[Tyr204Cys]
1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) R (87) unk -
c. [204A > T]; [814G > T] p. [Arg68Ser]; [Gly272*] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 1cPKU R R (87) NR (1) -
c. [204A > T]; [1045 T > C] p. [Arg68Ser];
[Ser349Pro]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R (87) NR (1) -
c. [204A > T]; [1055delG] p. [Arg68Ser];
[Gly352Valfs*48]
1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) R (87) unk - NR
c. [204A > T]; [1162G > A] p. [Arg68Ser];
[Val388Met]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R (87) R
(27.5)
-
c. [204A > T]; [1222C > T] p. [Arg68Ser];
[Arg408Trp]




0 2 (mPKU, cPKU) R (87) NR (1) -
c. [204A > T]; [1315 + 1G >
A]
p. [Arg68Ser]; [?] 1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) R (87) NR (0) -
c. [261C > A]; [1065 + 1G >
A]
p. [Ser87Arg]; [?] 1 (0.38) 1 (0/
1)
- - 0 1 (mHP, H0 2.4 mg
%, minus 8 %)
R (82) unk -




1 (0.38) - - 1 (1/
0)
1 (cPKU) minus 36 % 0 no data unk NR (1) - unclear
c. [284_286delTCA]; [441 +
5G > T]
p. [Ile95del]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NRb -
c. [284_286delTCA];
[1243G > A]
p. [Ile95del]; [Asp415Asn] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data unk R (93) -
c. [311C > A]; [442-5C > G] p. [Ala104Asp]; [?] 1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) R (26) R -
c. [311C > A]; [1222C > T] p. [Ala104Asp];
[Arg408Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (26) NR (1) -
c. [331C > T]; [782G > A] p. [Arg111*]; [Arg261Gln] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) Ra
(38.5)
-
c. [331C > T]; [1222C > T] p. [Arg111*]; [Arg408Trp] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [434A > T]; [1222C > T] p. [Asp145Val];
[Arg408Trp]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data unk NR (1) - R













Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)




c. [441 + 5G > T]; [473G >
A]
p. [?]; [Arg158Gln] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) NRb R (10) -
c. [441 + 5G > T]; [631C >
A]
p. [?]; [Pro211Thr] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data NRb R (72) -
c. [441 + 5G > T]; [782G >
A]
p. [?]; [Arg261Gln] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) NRb Ra
(38.5)
-
c. [441 + 5G > T]; [838G >
A]
p. [?]; [Glu280Lys] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NRb NR
(1.95)
-
c. [441 + 5G > T]; [1045 T >
G]
p. [?]; [Ser349Ala] 1 (0.38) - - 1 (1/
0)
1 (cPKU) minus 41 % 0 no data NRb unk - R
c. [442-2A > C]#; [442-2A >
C]#
p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [464G > C]; [1223G > A] p. [Arg155Pro];
[Arg408Gln]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk R
(49.7)
-
c. [464G > C]; [510-?-706
+ ?del]
p. [Arg155Pro]; [Ex6del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [472C > T]; [472C > T] p. [Arg158Trp];
[Arg158Trp]
1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) unk unk -
c. [472C > T]; [754C > T] p. [Arg158Trp];
[Arg252Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (1) -
c. [473G > A]; [473G > A] p. [Arg158Gln];
[Arg158Gln]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (10) R (10) -
c. [473G > A]; [526C > T] p. [Arg158Gln]; [Arg176*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (10) NR (1) -
c. [473G > A]; [814G > T] p. [Arg158Gln]; [Gly272*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (10) NR (1) -
c. [473G > A]; [1066-11G >
A]
p. [Arg158Gln]; [?] 3 (1.15) - - 3 (0/
3)
0 3 (3 cPKU) R (10) NR (0) -
c. [473G > A]; [1169A > G] p. [Arg158Gln];
[Glu390Gly]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 5 R R (10) R
(72.5)
-
c. [473G > A]; [1222C > T] p. [Arg158Gln];
[Arg408Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (10) NR (1) -
c. [473G > A]; [169-?_352 +
?del]
p. [Arg158Gln]; [Ex3del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (10) unk -
c. [473G > T]; [782G > C] p. [Arg158Trp];
[Arg261Pro]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -


















c. [493G > A]; [493G > A] p. [Ala165Thr];
[Ala165Thr]
2 (0.77) - - 2 (1/
1)
1 (cPKU) minus 36 % 1 (cPKU) minus 0 % no data unk unk - unclear unclear
c. [493G > C]; [1169A > G] p. [Ala165Pro]; [Glu390Gly] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data unk R
(72.5)
-
c. [500A > T]; [1066-11G >
A]
p. [Asn167Ile]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data unk NR (0) - R
c. [504C > A]#; [898G > T] p. [Tyr168*]; [Ala300Ser] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data unk R (31) - NR
c. [506G > A]; [1066-3C > T] p. [Arg169His]; [?] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data unk R -
c. [509 + 1G > A]; [561G >
A]
p. [?]; [Trp187*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [529G > C]; [561G > A] p. [Val177Leu]; [Trp187*] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data unk NR (0) - R
c. [569 T > C]; [796A > C]# p. [Val190Ala]; [Thr266P] 1 (0.38) - - 1 (0/
1)







1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk R (41) -
c. [581 T > C]; [842C > T] p. [Leu194Pro];
[Pro281Leu]
1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) unk NR (1) -
c. [593_614del22]; [969 +
1G > A]
p. [Tyr198Cysfs*136]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [631C > A]; [782G > A] p. [Pro211Thr];
[Arg261Gln]




2 (mPKU, cPKU) 0 4 mHP R R (72) Ra
(38,5)
-
c. [631C > A]; [1066-11G >
A]
p. [Pro211Thr]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 10 R R (72) NR (0) -
c. [632delC]; [1066-11G >
A]
p. [Pro211Hisfs*130]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [635 T > C]; [1066-11G >
A]
p. [Leu212Pro]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [638 T > C]; [638 T > C] p. [Leu213Pro];
[Leu213Pro]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [638 T > C]; [727C > T] p. [Leu213Pro]; [Arg243*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (1) -
c. [648C > G]; [838G > A] p. [Tyr216*]; [Glu280Lys] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR
(1.95)
- NR




















c. [653G > T]; [1066-11G >
A]
p. [Gly218Val]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [663_664delAG]; [912 +
1G >A]
p. [Asp222*]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) unk -
c. [671 T > C]; [671 T > C] p. [Ile224Thr]; [Ile224Thr] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) unk unk -
c. [682G > A]#; [1066-
11G > A]
p. [Glu228Lys]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -




1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) R (25) unk -
c. [722G > A]; [722G > A] p. [Arg241His];
[Arg241His]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R (23) R (23) -
c. [722G > A]; [782G > A] p. [Arg241His];
[Arg261Gln]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R (23) Ra
(38,5)
-
c. [722G > A]; [838_842 +
3del8]
p. [Arg241His]; [His280*] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R (23) unk - NR
c. [722G > A]; [842 + 1G >
A]
p. [Arg241His]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data R (23) unk -
c. [722G > A]; [1066-11G >
A]
p. [Arg241His]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data R (23) NR (0) -
c. [727C > T]; [727C > T] p. [Arg243*]; [Arg243*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [727C > T]; [842C > T] p. [Arg243*]; [Pro281Leu] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [727C > T]; [912 + 1G >
A]
p. [Arg243*]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) unk -
c. [727C > T]; [1042C > G] p. [Arg243*]; [Leu348Val] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) R (41) -
c. [727C > T]; [1066-11G >
A]
p. [Arg243*]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (0) -
c. [727C > T]; [?] p. [Arg243*]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) - -
c. [728G > A]; [913-7A > G] p. [Arg243Gln]; [?] 1 (0.38) - - - 0 1 (unk) R (23) unk -
c. [728G > A]; [912 + 1G >
A]
p. [Arg243Gln]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) R (23) unk -
c. [728G > A]; [1055delG] p. [Arg243Gln];
[Gly352Valfs*48]
2 (0.77) - - 2 (0/
2)













Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)
c. [728G > A]; [1208C > T] p. [Arg243Gln];
[Ala403Val]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 6 mHP R R (23) R (32) -
c. [734 T > C]; [1315 + 1G>
A]
p. [Val245Ala]; [?] 1 (0.38) 1 (0/
1)
- - 0 1 (mHP, H0 2.4 mg
%, minus 4 %)
R (50) NR (0) -
c. [754C > T]; [838G > A] p. [Arg252Trp];
[Glu280Lys]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR
(1.95)
-
c. [754C > T]; [838_842 +
3del8]
p. [Arg252Trp]; [His280*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) unk - NR
c. [754C > T]; [1042C > G] p. [Arg252Trp];
[Leu348Val]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) R (41) -
c. [754C > T]; [1045 T > G] p. [Arg252Trp];
[Ser349Ala]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) minus 51 % 0 no data NR (1) unk - R
c. [754C > T]; [1055delG] p. [Arg252Trp];
[Gly352Valfs*48]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) unk - NR
c. [754C > T]; [1066-11G >
A]
p. [Arg252Trp]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (0) -
c. [754C > T]; [1208C > T] p. [Arg252Trp];
[Ala403Val]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 3 R NR (1) R (32) -
c. [754C > T]; [1241A > G] p. [Arg252Trp];
[Tyr414Cys]
1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 4 R NR (1) Ra (36) -
c. [755G > A]; [782G > A] p. [Arg252Gln];
[Arg261Gln]
1 (0.38) - - 1 (1/
0)





c. [755G > A]; [1066-11G >
A]
p. [Arg252Gln]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk
(3–24)
NR (0) -
c. [770G > A]; [932 T > C] p. [Gly257Asp];
[Leu311Pro]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (1) -
c. [776C > T]; [1066-11G >
A]
p. [Ala259Val]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) unk
(2)
NR (0) -
c. [776C > T]; [1222C > T] p. [Ala259Val];
[Arg408Trp]
2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) unk
(2)
NR (1) -




1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk
(2)
unk -
c. [781C > G]#; [913-7A > G] p. [Arg261Gly]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [781C > T]; [781C > T] p. [Arg261*]; [Arg261*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [781C > T]; [782G > A] p. [Arg261*]; [Arg261Gln] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) Ra
(38.5)
-













Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)
1 (0/
1)




- - 8 (6/
2)







c. [782G > A]; [782G > C] p. [Arg261Gln];
[Arg261Pro]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) Ra
(38,5)
unk -
c. [782G > A]; [814G > T] p. [Arg261Gln]; [Gly272*] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) Ra
(38,5)
NR (1) -
c. [782G > A]; [838G > A] p. [Arg261Gln];
[Glu280Lys]
1 (0.38) - - 1 (0/
1)





c. [782G > A]; [842 + 1G >
A]
p. [Arg261Gln]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) Ra
(38,5)
unk -
c. [782G > A]; [912 + 1G >
A]
p. [Arg261Gln]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) Ra
(38,5)
unk -
c. [782G > A]; [1045 T > C] p. [Arg261Gln];
[Ser349Pro]









c. [782G > A]; [1055delG] p. [Arg261Gln];
[Gly352Valfs*48]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) Ra
(38,5)
unk - NR
c. [782G > A]; [1066-11G > A] p. [Arg261Gln]; [?] 4 (1.53) - - 4 (0/
4)
0 4 (4 cPKU) Ra
(38,5)
NR (0) -
c. [782G > A]; [1068C > G] p. [Arg261Gln]; [Tyr356*] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) Ra
(38,5)
NR (1) -
c. [782G > A]; [1162G > A] p. [Arg261Gln];
[Val388Met]
1 (0.38) - - 1 (0/
1)





c. [782G > A]; [1208C > T] p. [Arg261Gln];
[Ala403Val]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 6 mHP R Ra
(38,5)
R (32) -
c. [782G > A]; [1222C > T] p. [Arg261Gln];
[Arg408Trp]




0 4 (1 mPKU, 3 cPKU) Ra
(38,5)
NR (1) -
c. [782G > A]; [1241A > G] p. [Arg261Gln];
[Tyr414Cys]
1 (0.38) - 1 (1/
0)





c. [782G > A]; [1315 + 1G >
A]
p. [Arg261Gln]; [?] 5
(1.915)
- - 5 (0/
5)
0 5 (5 cPKU) Ra
(38,5)
NR (0) -
c. [782G > A]; [510-?-706
+ ?del]
p. [Arg261Gln]; [Ex6del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) Ra
(38,5)
unk -
c. [782G > C]; [1241A > G] p. [Arg261Pro];
[Tyr414Cys]
1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 2 PKU R; 1 PKU NR unk Ra (36) -
c. [782G > C]; [1315 + 1G >
A]
p. [Arg261Pro]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -


















c. [814G > T]; [1042C > G] p. [Gly272*]; [Leu348Val] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) R (41) -
c. [814G > T]; [1045 T > C] p. [Gly272*]; [Ser349Pro] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [814G > T]; [1066-11G >
A]
p. [Gly272*]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (0) -
c. [814G > T]; [1162G > A] p. [Gly272*]; [Val388Met] 1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 no data NR (1) R
(27.5)
-
c. [814G > T]; [1169A > G] p. [Gly272*]; [Glu390Gly] 2 (0.77) - 2 (2/
0)
- 2 (mPKU) 0 2 R NR (1) R
(72.5)
-
c. [814G > T]; [1208C > T] p. [Gly272*]; [Ala403Val] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data NR (1) R (32) -
c. [814G > T]; [1222C > T] p. [Gly272*]; [Arg408Trp] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [829 T > G]; [1042C > G] p. [Tyr277Asp];
[Leu348Val]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data unk
(0–12)
R (41) -
c. [829 T > G]; [1066-11G >
A]
p. [Tyr277Asp]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk
(0–12)
NR (0) -
c. [833C > A]; [1315 + 1G >
A]
p. [Thr278Asn]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [837delC]#; [1315 + 1G >
A]
p. [His280Asnfs*61]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -











c. [838G > A]; [842 + 1G >
A]
p. [Glu280Lys]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR
(1.95)
unk -
c. [838G > A]; [869A > T]# p. [Glu280Lys];
[His290Leu]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR
(1.95)
unk -
c. [838G > A]; [898G > T] p. [Glu280Lys];
[Ala300Ser]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data NR
(1.95)
R (31) -
c. [838G > A]; [1055delG] p. [Glu280Lys];
[Gly352Valfs*48]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR
(1.95)
unk - NR
c. [838G > A]; [1066-11G >
A]
p. [Glu280Lys]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR
(1.95)
NR (0) -
c. [838G > A]; [1066-3C > T] p. [Glu280Lys]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) NR
(1.95)
R -




















c. [838G > A]; [1222C > T] p. [Glu280Lys];
[Arg408Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR
(1.95)
NR (1) -
c. [838G > A]; [1243G > A] p. [Glu280Lys];
[Asp415Asn]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data NR
(1.95)
R (93) -
c. [841C > T]; [1315 + 1G >
A]
p. [Pro281Ser]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [842 + 1G > A]; [1066-
11G > A]
p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [842 + 3G > C]; [842 +
3G > C]
p. [?]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) unk unk -
c. [842C > T]; [842C > T] p. [Pro281Leu];
[Pro281Leu]
2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) NR (1) NR (1) -
c. [842C > T]; [898G > T] p. [Pro281Leu];
[Ala300Ser]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 3 R NR (1) R (31) -
c. [842C > T]; [926C > T] p. [Pro281Leu]; [A309Val] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) R (44) -
c. [842C > T]; [1042C > G] p. [Pro281Leu];
[Leu348Val]
2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) NR (1) R (41) -
c. [842C > T]; [1066-11G >
A]
p. [Pro281Leu]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (0) -
c. [842C > T]; [1222C > T] p. [Pro281Leu];
[Arg408Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) NR (1) -
c. [842C > T]; [1241A > G] p. [Pro281Leu];
[Tyr414Cys]




2 (mPKU, cPKU) 0 6 R; 1 NR NR (1) Ra (36) -
c. [842C > T]; [1315 + 1G >
A]
p. [Pro281Leu]; [?] 3 (1.15) - - 3 (1/
2)
1 (cPKU) minus 33 % 2 (2 cPKU) 6 cPKU NR NR (1) NR (0) -
c. [887A > G]#; [1222C > T] p. [Asp296Gly];
[Arg408Trp]
1 (0.38) - - 1 (1/
0)
1 (cPKU) minus 36 % 0 no data unk NR (1) - unclear
c. [896 T > G]; [1222C > T] p. [Phe299Cys];
[Arg408Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk
(3)
NR (1) -
c. [896 T > G]; [169-?_352
+ ?del]
p. [Phe299Cys]; [Ex3del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk
(3)
unk -
c. [898G > T]; [1045 T > C] p. [Ala300Ser];
[Ser349Pro]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 4 R R (31) NR (1) -
c. [898G > T]; [1066-11G >
A]
p. [Ala300Ser]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 16 R R (31) NR (0) -
c. [898G > T]; [1315 + 1G >
A]
p. [Ala300Ser]; [?] 2 (0.77) 2 (2/
0)













Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)
c. [912 + 1G > A];
[1055delG]
p. [?]; [Gly352Valfs*48] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk - NR
c. [912 + 1G > A]; [1315 +
1G > A]
p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [912 + 2 T > C]#;
[1042C > G]
p. [?]; [Leu348Val] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk R (41) -
c. [913-8A > G]#; [1315 +
1G > A]
p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk NR (0) -
c. [1042C > G]; [1042C > G] p. [Leu348Val];
[Leu348Val]
1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 3 PKU R R (41) R (41) -
c. [1042C > G]; [1066-
11G > A]
p. [Leu348Val]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (41) NR (0) -
c. [1042C > G]; [1169A > G] p. [Leu348Val];
[Glu390Gly]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 3 R R (41) R
(72.5)
-
c. [1042C > G]; [1222C > T] p. [Leu348Val];
[Arg408Trp]
1 (0.38) - - 1 (0/
1)
0 1 (cPKU) R (41) NR (1) -
c. [1045 T > C]; [1066-3C >
T]
p. [Ser349Pro]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) R -
c. [1045 T > C]; [1162G > A] p. [Ser349Pro];
[Val388Met]
2 (0.77) - - 2 (1/
1)
1 (cPKU) minus 72 % 1 (cPKU) minus
20 %
2 R; 4 cPKU NR NR (1) R
(27.5)
-
c. [1045 T > C]; [1169A > G] p. [Ser349Pro];
[Glu390Gly]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 5 R NR (1) R
(72.5)
-
c. [1045 T > C]; [1243G > A] p. [Ser349Pro];
[Asp415Asn]
1 (0.38) 1 (0/
1)
- - 0 1 (mHP) NR (1) R (93) -
c. [1045 T > C]; [442-?_509
+ ?del]
p. [Ser349Pro]:Ex5del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (1) unk -








1 (mPKU) minus 71.5 % 1 (cPKU) minus 7 % 1 R unk unk - R R
c. [1055delG]; [1055delG] p. [Gly352Valfs*48];
[Gly352Valfs*48]
7 (2.68) - - 7 (0/
7)
0 7 (7 cPKU) unk unk - NR NR
c. [1055delG]; [1066-11G >
A]
p. [Gly352Valfs*48]; [?] 2 (0.77) - - 2 (0/
2)
0 2 (2 cPKU) unk NR (0) - NR
c. [1055delG]; [1208C > T] p. [Gly352Valfs*48];
[Ala403Val]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data unk R (32) - NR
c. [1065 + 1G > A];
[1169A > G]
p. [?]; [Glu390Gly] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data unk R
(72.5)
-
c. [1066-2A > T]#; [1169A >
G]
p. [Glu390Gly]; [?] 1 (0.38) - - - 1 ('unk) 0 no data unk R
(72.5)
-













Table 1 Genotypes observed in French patients with phenylketonuria. Association with clinical phenotypes and response to BH4 loading-test (Continued)








c. [1066-11G > A];
[1162G > A]
p. [?]; [Val388Met] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (0) R
(27.5)
-
c. [1066-11G > A];
[1196 T > C]#
p. [?]; [Val399Ala] 1 (0.38) - - 1 (1/
0)
1 (cPKU) minus 97 % 0 no data NR (0) unk - R
c. [1066-11G > A]; [1199 +
1G> C]




1 (cPKU) minus 37.5 % 2 (mPKU, cPKU) no data NR (0) unk - unclear
c. [1066-11G > A];
[1222C > T]
p. [?]; [Arg408Trp] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (0) NR (1) -
c. [1066-11G > A];
[1223G > A]
p. [?]; [Arg408Gln] 1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 no data NR (0) R
(49.7)
-
c. [1066-11G > A];
[1241A > G]
p. [?]; [Tyr414Cys] 4 (1.53) - 4 (3/
1)
- 3 (mPKU) 1 (mPKU) minus
21 %
18 R; 2 NR NR (0) Ra (36) -
c. [1066-11G > A]; [1315 +
1G>A]
p. [?]; [?] 3 (1.15) - - 3 (0/
3)
0 3 (3 cPKU) NR (0) NR (0) -
c. [1066-11G > A]; [510-
?_706 + ?dup]#
p. [?]; [Ex6dup] 1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) NR (0) unk -
c. [1066-11G > A]; [?] p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (0) - -
c. [1066-3C > T]; [1180G >
T]#
p. [?]; [Asp394Tyr] 1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) R unk -
c. [1068C > G]; [1162G > A] p. [Tyr356*]; [Val388Met] 1 (0.38) - - 1 (1/
0)
1 (cPKU) 0 no data NR (1) R
(27.5)
-
c. [1139C > T]; [1180G > T]# p. [Thr380Met];
[Asp394Tyr]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data R unk -
c. [1139C > T]; [1-?_60
+ ?del]#
p. [Thr380Met]; [Ex1del] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R unk -
c. [1162G > A]; [1162G > A] p. [Val388Met];
[Val388Met]
1 (0.38) - - 1 (0/
1)





c. [1162G > A]; [1169A > G] p. [Val388Met];
[Glu390Gly]
1 (0.38) - 1 (1/
0)





c. [1162G > A]; [1223G > A] p. [Val388Met];
[Arg408Gln]
1 (0.38) - - 1 (1/
0)









1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data unk R (32) -
c. [1169A > G]; [1241A > G] p. [Glu390Gly];
[Tyr414Cys]
1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 no data R
(72.5)
Ra (36) -


















c. [1199 + 1G> C]; [1199 +
1G> C]
p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) unk unk -
c. [1208C > T]; [1222C > T] p. [Ala403Val];
[Arg408Trp]




- 2 (mHP, mPKU) 0 6 R R (32) NR (1) -
c. [1208C > T]; [1315 +
1G > A]
p. [Ala403Val]; [?] 1 (0.38) 1 (1/
0)
- - 1 (mHP) 0 9 R R (32) NR (0) -




- - 5 (0/
5)
0 5 (5 cPKU) NR (1) NR (1) -
c. [1222C > T]; [1223G > A] p. [Arg408Trp];
[Arg408Gln]
1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data NR (1) R
(49.7)
-








2 (mPKU) minus 43 %,
minus 66 %
3 (2 mPKU, 1cPKU) 30 R; 6 NR NR (1) Ra (36) -
c. [1222C > T]; [1315 +
1G > A]
p. [Arg408Trp]; [?] 3 (1.15) - - 3 (0/
3)
0 3 (3 cPKU) NR (1) NR (0) -
c. [1222C > T]; [?] p. [Arg408Trp]; [?] 1 (0.38) - 1 (0/
1)
- 0 1 (mPKU) NR (1) - -
c. [1223G > A]; [1241A > G] p. [Arg408Gln];
[Tyr414Cys]









c. [1241A > G]; [1315 +
1G > A]




2 (mPKU, cPKU) minus
34 %, minus 39 %
1 (cPKU) minus
21 %
24 PKU R; 1 PKU NR Ra
(36)
NR (0) -
c. [1241A >G]; [169-?_352
+ ?del]
p. [Tyr414Cys]; [Ex3del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) Ra
(36)
unk -
c. [1243G >A]; [169-?_352
+ ?del]
p. [Asp415Asn]; [Ex3del] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) 0 no data R (93) unk -
c. [1249 T > A]; [1315 +
1G > A]
p. [Tyr417Asn]; [?] 1 (0.38) - 1 (1/
0)
- 1 (mPKU) minus 37 % 0 no data unk NR (0) - unclear
c. [1315 + 1G>A]; [1-?_60
+ ?del]#
p. [?]; [Ex1del] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) NR (0) unk -
c. [?]; [?] p. [?]; [?] 1 (0.38) - - 1 (0/
1)
0 1 (cPKU) - - -
Freq frequency, MLPA multiplex ligation-dependent probe amplification, mut mutation, NR non responsive, PRA predicted residual activity, R responsive, unclear BH4-response rate comprised between 30 and 40 %, unk













thought moderate, in their Phe concentration (minus
31 % and minus 33 %).
Confrontation of genotypes and BH4-loading tests
concluded that only patients with mHP carrying 2
responsive mutations are always BH4-responders.
Response to BH4 cannot be predicted in other patients
carrying either two or one responsive mutations. How-
ever, the milder the phenotype is, the most probable the
BH4 test is positive.
Associations of response to BH4-loading test with type
and location of mutations
Any mutation other than missense mutation is predictive
of a non-response. Indeed, first, 98.2 % of responsive pa-
tients carried at least one missense mutation. Second, fre-
quency of BH4-responders was higher in carriers of 2
missense mutations (45.2 %) than in carriers of 1 missense
mutation combined with another type of mutations – such
as frameshift, nonsense or splice-site mutation (29.0 %)
[Fisher exact test, see Additional file 5: Figure S5]. Third,
genotypes combining frameshift, in-frame, nonsense
and splice-site mutations were non-responsive, except
in two cases where combinations of 2 splice site mu-
tations gave positive - though moderate – responses
(minus 31 % and 37.5 %).
We looked for a possible link between BH4-
responsiveness and the localisation of mutations. The
oligomerization domain seems highly relevant to respon-
siveness since more responders were found in carriers of
one missense mutation in the oligomerization domain
(71.4 %) than in carriers of one missense mutation in
the catalytic (31.4 %) or regulatory (27.2 %) domains
(p = 0.0006; Fisher exact test; [see Additional file 6:
Figure S6]). In addition, even in a single domain there
are differences between exons. Thus, more BH4-
responders were found in carriers of missense mutations
in exon 11, 12 or 8 while carriers of missense mutations in
exon 7 were more often BH4-unresponsive (Fisher exact
test; [Additional file 7: Figure S7]).
Discussion
In the present study, patients were classified according
to pre-treatment Phe concentration following French
and European recommendations into three phenotype
categories i.e. mHP (180–600 μmol/L), mPKU (600–
1200 μmol/L) and cPKU (>1200 μmol/L Phe) [5, 22].
While recent European consensus publication is still
pending, NIH American conference consensus, which
was published at a time when our study was com-
pleted, proposed 5 categories, namely mHP not re-
quiring treatment (<360 μmol/L), mild HP-gray zone
(360–600 μmol/L), mPKU (600–900 μmol/L), moder-
ate PKU (900–1200 μmol/L) and cPKU(>1200 μmol/L
Phe) [26]. This different classification system has to
be kept in mind when considering the findings and
conclusions in our mHP group.
Our multicentric cohort study represents respectively
17.4 % of global cPKU and mPKU and 2.6 % of global
mHP diagnosed in France since the beginning of the
neonatal screening in the seventies (data from the
French neonatal screening association AFDPHE, [27]).
In this study, in which we included only 364 patients
with both genetic testing and BH4 testing, frequency of
mHP is 9 %. Frequency of mHP in all genotyped individ-
uals (n = 701) in our center is 19.3 %, which is higher
than the frequency in the 364 patients included in this
study (9 %), but still not representative of the 39.4 % of
mHP observed among the whole PKU patients screened
in metropolitan France since the beginning of the
neonatal screening ([27]. Underrepresentation of pa-
tients with the milder phenotypes can be partly ex-
plained by the fact that there is no recommendation
for BH4-testing in patients with Phe concentration
under 480 μmol/L. Several mHP are lost to follow-up,
in a center dependent manner, and they miss either
molecular analysis and/ or BH4 testing.
Investigation of the PAH gene combining dHPLC,
sequencing and MLPA allowed us to reach a 99.05 %
mutation detection rate, in agreement with results found
in Australia: 99.0 % [28], Austria: 98.6 %, [29] or Turkey:
97.3 % [30]. dHPLC is a useful method for screening a
large set of samples. It proved to be reliable in our hands
and cost effective by narrowing down the number of
exons needed to be sequenced. However, because of the
chemistry of the method, the genetic variants may not
be clearly separated. Now several factors argue that dir-
ect sequencing should be the first-line test to identify
mutations in the PAH gene. Sequencing is carried out
faster and costs have dropped down. In addition, next
generation sequencing is spreading quickly and allows
analyzing a large number of patients in a short time and
at costs going lower and lower. Next generation se-
quencing also allows analyzing the whole gene includ-
ing introns and regulatory regions. A spectrum of 127
mutations is reported in this study, including 82 mu-
tations with unknown BH4-responsiveness, according
to information available in the literature. This study en-
ables us to classify 5 of them as responsive (c.434A > T,
c.500A > T, c.529G > C, c.1045 T >G and c.1196 T > C).
The mutation c.1196 T > C (p.Val399Ala) is positioned
four nucleotides upstream the exon/intron junction in
exon 11 and one base upstream the 5’ splice-site. Exon 11
is particularly vulnerable to mutations affecting
splicing regulatory elements [31]. Thus, c.1197A > T
and c.1199G > A have been shown to lead to exon
skipping [32]. Minigene assays are needed to determine if
the mutation c.1196 T > C could or not disrupt the bal-
ance between exonic splicing enhancers and silencers [31].
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The c.434A > T (p.Asp145Val) mutation involves the
substitution of a charged amino acid by a hydrophobic
residue. The c.500A > T (p.Asn167Ile) mutation involves
the substitution of a polar residue by a hydrophobic
residue. The c.529G > C (p.Val177Leu) mutation leads to
the substitution of a hydrophobic residue, mostly buried in
the loop between C2 and C3 alpha helices [33], by a residue
with similar physical and chemical properties. Another mu-
tation affecting the same nucleotide, c.529G >A (p.Val177-
Met), had previously been described as BH4-responsive
[10]. Residue Ser349 is an essential amino acid in the active
site of the gene. The substitution of Serine349 by Alanine
(c.1045 T >G) removes the hydroxyl group within hydro-
gen bonding distance of the iron-chelating H285 required
for PAH catalytic activity. Missense mutations leading to
modifications of either the protein overall hydrophobicity
or the ability to form hydrogen bonds within the polypep-
tide backbone or between side chains may impact on the
folding/conformation of PAH. Gersting and colleagues sug-
gested that the consequences of these missense mutations
might be compensated for by pharmacological doses of
BH4 [7]. However, further functional studies are needed to
verify that restoration of the enzymatic activity is pos-
sible by the addition of BH4 [7, 34, 35]. Another
group of five mutations fitted the criteria for classifi-
cation as responsive mutations but were not recognized
as such. Indeed, there were observed in patients with a
BH4-responsive rate comprised between 30 and 40 per-
cent and we do believe that there responsiveness should
be subsequently assessed by the long-term achievement of
blood Phe target concentration under BH4 treatment.
The position and the nature of the mutation influence
the activity of PAH enzyme, which in turn determines
the patient phenotype [21]. Our study suggests that for
any genotype to be potentially BH4-responsive it needs
to contain one missense mutation. Indeed, 98.2 % of the
responsive patients in this study carried at least one mis-
sense mutation. Conversely, homozygous or compound
heterozygous patients carrying any other type of muta-
tions are likely not to be BH4-responders, and administer-
ing a long term BH4-therapy to them will not yield an
appropriate cost-effectiveness ratio. It is true that combi-
nations of some splice-site mutations were reported previ-
ously to be associated with a partial BH4-responder
phenotype. The explanation was that those mutations
were not fully penetrant, determining a phenotype with
persistent residual activity [36]. However, for these pa-
tients, based on our experience, BH4 would have rather
limited effect in improving dietary Phe tolerance.
In this study, the frequency of BH4-responders reached
31.6 %. It is of note that, if the threshold of responsiveness
was more severe (decrease of Phe concentration >40 %),
the overall responsive rate would be 22.9 %, which is actu-
ally a more reasonable estimate of patients treated with
BH4 in France (139 patients: data may 2013). Zurfluh and
colleagues [10] postulated that the average frequency of
patients potentially BH4-responsive in European popula-
tions is 55 %. However, these authors considered the BH4-
responsive mutations to be dominant in compound het-
erozygous patients and classified carriers of one BH4-
responsive allele as systematically responsive. This is not
always true. Two mutant monomers interact to constitute
the holoenzyme and there may be unexpected negative as
well as positive inter-allelic complementation in com-
pound heterozygous [4]. Indeed, we found that genotypes
carrying 1 or 2 responsive mutations cannot be expected
to be always BH4-responsive. Actually, only 66.7 % of
patients carrying 2 responsive mutations, 35.4 % of
patients carrying 1 responsive mutation and 1 non-
responsive mutation and 35.2 % of patients carrying 1
responsive mutation and 1 unclassified mutation were
effective BH4-responders. It must be stressed out that
BH4-responsiveness depends on the disease phenotype,
since 100 % of patients with mHP carrying two responsive
alleles were found to be BH4-responders whereas this
frequency was only 42.3 % for patients with cPKU.
Fourteen genotypes were assigned to both responsive
and non-responsive patients. Similar discordances involv-
ing some of these genotypes were already described in the
BioPKU database [2], as reported in Table 1. Indeed, while
the c. [1066-11G > A]; [1066-11G >A] genotype, associ-
ated with a null predicted residual activity, was observed
in five PKU non-responsive patients, one tPKU patient
carrying this genotype showed a positive BH4 responsive
test (H0 1356 μmol/L). However, this patient showed a
Phe decrease limited to 31 %. A second example is c.
[194 T > C]; [1222C > T] (p.[Ile65Thr]; [Arg408Trp])
genotype, associated both with one non-responsive tPKU
(H0 2760 μmol/L) and one responsive tPKU (H0
1380 μmol/L) with a Phe decrease limited to 32 %.
This dual BH4-responsiveness may be due to a BH4-
loading test performed under a rather strict low-Phe diet
with subnormal Phe concentrations. Indeed, in the case of
some mutations, the stimulation effect of BH4 on residual
enzymatic activity is weaker at low Phe concentrations,
as previously described for c.782G > A (p.Arg261Gln)
[4, 9, 34]. In our study, patients with p.[Arg261Gln];
[Arg261Gln] genotype and low Phe concentrations at
the beginning of BH4-loading test were found to be
BH4-unresponsive whereas patients with the same
genotype but higher Phe concentrations were found
to be responsive (Phe decrease of minus 66 %, minus
59 %, minus 38 %, minus 37 % and 0 % for basal Phe
concentration before testing of 1080, 1236, 768, 960
and 430 μmol/L respectively). Another reason for
dual responsiveness to BH4 is the intraday fluctuation
during the period of the loading test [10]. This is es-
pecially true if the decrease in blood Phe concentration at
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24 hour is around 30 to 40 %, like in two cPKU patients in
this study. This causes to mis-conclude that the pa-
tient is BH4-responsive while his genotype is pre-
dicted to be unresponsive. However, only failure of
long-term Phenylalanine dietary tolerance improve-
ment would definitively confirm that the patient is
unresponsive. A third reason is an interindividual
variability in BH4 intestinal absorption or in concen-
tration of cofactor required for PAH activity [9].
Lastly, a dual BH4-responsiveness can be due to pos-
sible variations in the protocol of the test [12, 20].
However, since the procedure was standardized (all
centers used the same BH4 dose, the same time of
follow-up and a common definition of responsive-
ness), discrepancies cannot be explained here by dif-
ferences in protocols. To note, recent data from the
European literature [14] showed that a 48 h-loading
test would allow a better recognition of late
responders . Here, a 24 h-BH4 loading test was used.
Some late-responsive patients may thus have been
misclassified as non-responders and some genotypes left
unclassified could have been assigned a responsiveness
status.
Conclusion
This study describe the correlation between PAH
genotyping and BH4 loading test in 364 French phenylke-
tonuria patients. We report here that 46 genotypes and
five mutations, whose BH4-responsiveness was previously
unknown, are BH4-responsive. Our observations addition-
ally suggest that mHP patients carrying two responsive al-
leles are likely to be always BH4-responders. Conversely,
patients with 2 non-responsive alleles as well as carriers of
combinations of frameshift, in-frame, nonsense, or splice-
site mutations are likely to not respond to BH4. For the
other cases, the presence of at least one missense respon-
sive mutation is necessary, but not sufficient, for the
patient to be responsive. In these patients, BH4-loading
test and long-term monitoring of dietary Phe tolerance
are the mainstay of the evaluation of BH4-responsiveness.
This study underscores the relevance of systematic in-
corporation of PAH genotyping together with BH4-loading
test in the clinical evaluation of BH4-responsiveness to help
distinguishing true response to BH4 administration.
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Additional files
Additional file 1: Figure S1. Frequency of positive BH4-loading test is
higher in mildest PKU phenotypes. Error bars represent the 95 % confidence
intervals. Fisher exact test, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05. (TIF 32 kb)
Additional file 2: Figure S2. The 5 mutations identified in this study as
being BH4-responsive are localized in the catalytic domain of phenylalanine
hydroxylase. The PAH monomer is drawn as a ribbon representation
complexed with tetrahydrobiopterin (BH4 orange balls), thienylalanine
(analog substrate) and iron (red sphere). The N-terminal regulatory domain
(residues 103 – 142) is in blue, the catalytic domain (residues 143–410) is in
green and the dimerization motif (residues 411–427) is in purple. Mutated
aminoacids are indicated in red. (TIF 1429 kb)
Additional file 3: Figure S3. PAH secondary structure. Alpha-helices,
beta-strands and turns across the regulatory, catalytic and oligomerization
domains are indicated. Important residues are represented as well as the
position of the five mutations identified in this study as being BH4-
responsive. ARS: Autoregulatory sequence, CBR: Cofactor binding region.
(TIF 315 kb)
Additional file 4: Figure S4. Percentage of positive BH4 loading tests
depending on responsiveness of both alleles in the different severity
groups. The diagram shows that frequency of BH4 positive test in mHP
patients carrying 2 responsive alleles is 100 %, whereas this percentage is
85.7 % in patients with mPKU and 42.3 % in patients with cPKU. A similar
trend is observed for patients carrying only 1 BH4-responsive mutation.
The 2 patients with tPKU and 2 non-responsive alleles classified as BH4-
responders, moderately lowered the Phe concentrations (minus 31 % and
minus 33 %). This decrease would be clinically irrelevant as developed in
the discussion and highlights the importance of combining genotyping
and BH4 test before classifying a patient as BH4 responsive or not. Fisher
exact test, ***p ≤ 0.001, **p ≤ 0.01, *p≤ 0.05. (TIF 44 kb)
Additional file 5: Figure S5. Percentage of positive BH4-loading tests
depending on the type of each of the two mutations of the genotypes.
Missense mutations significantly correlate with positive BH4 loading test
more frequently than any other type of mutation. miss: missence. ns:
nonsense.fs: frameshift. del: deletion. dupl: duplication. Fisher exact test,
***p≤ 0.001, **p≤ 0.01, *p≤ 0.05. (TIF 1173 kb)
Additional file 6: Figure S6. Percentage of positive BH4 loading tests
depending on domain localization of alleles from each genotype. Fisher
exact test, ***p ≤ 0.001, **p ≤ 0.01, *p≤ 0.05. (TIF 33 kb)
Additional file 7: Figure S7. Percent of positive BH4-loading tests
depending on localization of missense mutations. This figure concern
only patients which carry at least one missense mutation (n = 311). Numbers
indicated in each column represent the global number of observations
(both responsive and non-responsive tests) for each column. ex: exon. Fisher
exact test, ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05. (TIF 53 kb)
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